Preview

Experimental and Clinical Gastroenterology

Advanced search

Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD)

https://doi.org/10.31146/1682-8658-ecg-218-10-168-174

Abstract

The aim of this review is to summarise the current knowledge on the role of adipokines on the development and progression of MAFLD. Discussion: diagnostic criteria for metabolic-associated liver disease (MAFLD) versus non-alcoholic fatty liver disease (NAFLD) are presented. The pathogenetic aspects of metabolic disorders in MAFLD are discussed. The potential role of various adipokines such as leptin, resistin, vasfastin, ghrelin, adiponectin and others is considered. Data from our own studies and foreign studies are presented. Conclusion: given the pandemic growth of MAFLD and its association with cardiovascular risk and obesity, the question of how to properly curate patients with comorbid to reduce risks is timely and highly relevant. Adipokines contribute significantly to the pathogenesis of MAFLD. Among all, leptin and adiponectin are the most promising and well studied. That is why strategies aimed at restoring leptin and adiponectin balance may have an impact on the course of MAFLD.

About the Authors

M. A. Livzan
Omsk State Medical University
Russian Federation


T. S. Krolevets
Omsk State Medical University
Russian Federation


M. I. Syrovenko
Omsk State Medical University
Russian Federation


References

1. Godoy-Matos A. F., Silva Júnior W. S., Valerio C. M. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 2020; 12: 60-65. doi: 10.1186/s13098-020-00570- y.

2. Vinnitskaya E. V., Sandler Yu.G., Bordin D. S. A new paradigm of non-alcoholic fatty liver disease: phenotypic diversity of metabolically associated fatty liver disease. Effective pharmacotherapy. 2020. 16(24): 54-63. (in Russ.) doi: 10.33978/2307-3586-2020-16-24-54-63.@@ Винницкая Е. В., Сандлер Ю. Г., Бордин Д. С. Новая парадигма неалкогольной жировой болезни печени: фенотипическое многообразие метаболически ассоциированной жировой болезни печени. Эффективная фармакотерапия. 2020; 16(24):54-63. doi: 10.33978/2307-3586-2020-16-24-54-63.

3. Kai En Chan and others. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism. 2022; 107(9): 2691-2700. doi: 10.1210/clinem/dgac321.

4. Liu J., Mu C., Li K., Luo H., Liu Y., Li Z. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis.Int J Public Health. 2021; 6(66):1604371. doi: 10.3389/ijph.2021.1604371.

5. Yamamura S., Eslam M., Kawaguchi T. et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020; 40: 3018-3030. doi: 10.1111/liv.14675.

6. Blomdahl J., Nasr P., Ekstedt M. et al. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism. 2021; 115: 154439. doi: 10.1016/j.metabol.2020.154439.

7. Rinella M. E., Lazarus J. V., Ratziu V., Francque S. M. et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 Jun 24: S0168-8278(23)00418-X. doi: 10.1016/j.jhep.2023.06.003.

8. Younossi Z., Anstee Q. M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018; 15: 11-20. doi: 10.1038/nrgastro.2017.109.

9. Mathews S. E., Kumar R. B., Shukla A. P. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. Curr. Opin. Endocrinol. Diabetes Obes. 2018, 25: 315-320. doi: 10.1097/MED.0000000000000432.

10. Eslam M., George J. Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease. Hepatol.Int. 2019; 13: 662-664. doi: 10.1007/s12072-019-09990- z.

11. Polyzos S. A., Perakakis N., Mantzoros C. S. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism. 2019; 96: 66-82. doi: 10.1016/j.metabol.2019.05.001

12. Francisco V., Pino J., González-Gay M. Á., Lago F., Karppinen J., Tervonen O., Mobasheri A., Gualillo O. A new immunometabolic perspective of intervertebral disc degeneration. Nat. Rev. Rheumatol. 2022; 18: 47-60. doi: 10.3390/biology11081237.

13. Redinger R. N. The pathophysiology of obesity and its clinical manifestations. Gastroenterol. Hepatol. 2007;3: 856-863.

14. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia. 2005; 48: 634-642. doi: 10.1002/hep.29465.

15. Kasper P., Martin A., Lang S., Kutting F., Goeser T., Demir M., Steffen H. M. NAFLD and cardiovascular diseases: A clinical review. Clin. Res. Cardiol. 2021; 110: 921-937. doi: 10.1161/HYPERTENSIONAHA.120.16547.

16. Armandi A., Rosso C., Caviglia G. P., Bugianesi E. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites. 2021;11: 155. doi: 10.3390/metabo11030155.

17. Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zuniga F. A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018; 17: 122. doi: 10.3390/biomedicines10071617.

18. Caussy C., Aubin A., Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr. Diab. Rep. 2021;21:15. doi: 10.1007/s11892-021-01383-7.

19. Byrne C. D., Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022; 24(2): 28-43. doi: 10.1111/dom.14484.

20. Recommendations of experts of the All-Russian Scientific Society of Cardiologists on the diagnosis and treatment of metabolic syndrome. Second revision. (in Russ.) (Available at: https://cyberleninka.ru/article/n/rekomendatsii-ekspertov-vserossiyskogo-nauchnogo-obschestva-kardiologovpo-diagnostike-i-lecheniyu-metabolicheskogo-sindroma-vtoroy-1 Accessed: 19.09.2023).@@ Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. (Электронный ресурс.) URL: https://cyberleninka.ru/article/n/rekomendatsii-ekspertov-vserossiyskogo-nauchnogo-obschestva-kardiologovpo-diagnostike-i-lecheniyu-metabolicheskogo-sindroma-vtoroy-1 (дата обращения: 19.09.2023).

21. Francisco V., Sanz M. J., Real J. T., Marques P., Capuozzo M., Ait Eldjoudi D., Gualillo O. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets? Biology (Basel). 2022;11(8):1237. doi: 10.3390/biology11081237.

22. Francisco V., Pino J., Campos-Cabaleiro V., Ruiz-Fernández C., Mera A., Gonzalez-Gay M. A., Gómez R., Gualillo O. Obesity, fat mass and immune system: Role for leptin. Front. Physiol. 2018, 9, 640. doi: 10.3390/ biology11081237.

23. Martínez-Uña M., López-Mancheño Y., Diéguez C., Fernández-Rojo M. A., Novelle M. G. Unraveling the role of leptin in liver function and its relationship with liver diseases.Int. J. Mol. Sci. 2020, 21, 9368. doi: 10.3390/ijms21249368.

24. Jiménez-Cortegana C., García-Galey A., Tami M., Del Pino P., Carmona I., López S., Alba G., Sánchez-Margalet V. Role of leptin in non-alcoholic fatty liver disease. Biomedicines. 2021; 9: 762.

25. Wree A., Kahraman A., Gerken G., Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion. 2011;83(1-2):124-133. doi: 10.1159/000318741.

26. Kelesidis T., Kelesidis I., Chou S., Mantzoros C. S. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010 Jan 19;152(2):93-100. doi: 10.7326/0003-4819-152-2-201001190-00008.

27. Rostás I., Pótó L., Mátrai P., Hegyi P. et al. In middle-aged and old obese patients, training intervention reduces leptin level: A meta-analysis. PLoS One. 2017;12(8). doi: 10.1371/journal.pone.0182801.

28. Krolevets T. S., Livzan M. A. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2018;(7):43-51. (In Russ.) @@ Кролевец Т. С., Ливзан М. А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;(7):43-51.

29. Hyogo H., Roy S., Cohen D. E. Restoration of gallstone susceptibility by leptin in C57BL/6J ob/ob mice. J Lipid Res. 2003;44(6):1232-1240. doi: 10.1194/jlr. M300029-JLR200.

30. Syrovenko M. I., Krolevets T. S., Livzan M. A. Liver fibrosis in non-alcoholic fatty liver disease and vascular comorbidity. Cardiovascular Therapy and Prevention. 2023; 22(6): 52. (In Russ.) @@ Сыровенко, М. И. Фиброз печени при неалкогольной жировой болезни печени и сосудистой коморбидности / М. И. Сыровенко, Т. С. Кролевец, М. А. Ливзан. Кардиоваскулярная терапия и профилактика. 2023; 22(6): 52.

31. Nguyen T. M.D. Adiponectin: Role in Physiology and Pathophysiology.Int. J. Prev. Med. 2020; 11: 136. doi: 10.4103/ijpvm.IJPVM_193_20.

32. Heydari M., Cornide-Petronio M. E., Jiménez-Castro M. B., Peralta C. Data on adiponectin from 2010 to 2020: Therapeutic target and prognostic factor for liver diseases? Int. J. Mol. Sci. 2020, 21, 5242 doi: 10.3390/ijms21155242.

33. Krolevets T. S., Livzan M. A., Syrovenko M. I. Liver fibrosis in nonalcoholic fatty liver disease: the role of adipokines and noninvasive assessment of the intestinal barrier. Evidence-based Gastroenterology. 2023; 12(2): 46-54. (In Russ.) doi: 10.17116/dokgastro20231202146.@@ Кролевец, Т. С. Фиброз печени при неалкогольной жировой болезни печени: роль адипокинов и неинвазивной оценки состояния кишечного барьера / Т. С. Кролевец, М. А. Ливзан, М. И. Сыровенко. Доказательная гастроэнтерология. 2023; 12(2): 46-54. doi: 10.17116/dokgastro20231202146.

34. Quiñones M., Fernø J., Al-Massadi O. Ghrelin and liver disease. Rev. Endocr. Metab. Disord. 2020, 21, 45-56. doi: 10.1007/s11154-019-09528-6.

35. Gruzdeva O. V., Borodkina D. A., Belik E. V., Akbasheva O. E., Palicheva E. I., Barbarash O. L. Ghrelin Physiology and Pathophysiology: Focus on the Cardiovascular System. Kardiologiia. 2019;59(3):60-67. (in Russ.) doi: 10.18087/cardio.2019.3.10220. @@ Груздева О. В., Бородкина Д. А., Белик Е. В., Акбашева О. Е., Паличева Е. И., Барбараш О. Л. Грелин - физиология и патофизиология: в центре внимания сердечно-сосудистая система. Кардиология. 2019;59(3):60-67. doi: 10.18087/cardio.2019.3.10220.

36. Yin Y., Wang Q., Qi M., Zhang C., Li Z., Zhang W. Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low-grade inflammation via blockade of Kupffer cell M1 polarization. J. Cell. Physiol. 2021, 236, 5121-5133. doi: 10.1002/jcp.30218.

37. Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mech. Ageing Dev. 2019, 178, 46-63. doi: 10.1016/j.mad.2019.01.004.

38. Verbovoi A. F., Tsanava I. A., Verbovaya N. I., Galkin R. A. Resistin is a marker of cardiovascular diseases. Obesity and metabolism. 2017;14(4):5-9. doi: 10.14341/OMET201745-9. @@ Вербовой А. Ф., Цанава И. А., Вербовая Н. И., Галкин Р. А. Резистин - маркер сердечно-сосудистых заболеваний. // Ожирение и метаболизм. - 2017. - Т. 14. - №. 4 - С. 5-9. doi: 10.14341/OMET201745-9.

39. Steppan C. M., Bailey S. T., Bhat S., Brown E. J., Banerjee R. R., Wright C. M., Patel H. R., Ahima R. S., Lazar, M. A. The hormone resistin links obesity to diabetes. Nature. 2001, 409, 307-312.

40. Muse E. D., Obici S., Bhanot S. et al. Role of resistin in diet-induced hepatic insulin resistance. J. Clin. Investig. 2004, 114, 232-239. doi: 10.1172/JCI21270.

41. Wen F., Shi Z., Liu X., Tan Y. et al. Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis through AMPK/PGC-1α Signaling Pathway in Male NAFLD Mice. Horm. Metab. Res. 2021; 53:132-144.

42. Livzan M. A., Gaus O. V., Nikolaev N. A., Krolevetz T. S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;170(10): 57-65. (In Russ.) doi: 10.31146/1682-8658-ecg-170-10-57-65.@@ Ливзан М. А., Гаус О. В., Николаев Н. А., Кролевец Т. С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10): 57-65. doi: 10.31146/1682-8658-ecg-170-10-57-65.

43. Gencer B. et al. Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. Atherosclerosis. 2016; 245: 181-186. doi: 10.1016/j.atherosclerosis.2015.12.004.

44. Janke J., Engeli S., Boschmann M., Adams F., Böhnke J., Luft F. C., Sharma A. M., Jordan J. Retinol-binding protein 4 in human obesity. Diabetes. 2006 Oct;55(10):2805-10. doi: 10.2337/db06-0616.

45. Liu Y., Mu D., Chen H., Li D., Song J., Zhong Y., Xia M. Retinol-Binding Protein 4 Induces Hepatic Mitochondrial Dysfunction and Promotes Hepatic Steatosis. J. Clin. Endocrinol. Metab. 2016, 101, 4338-4348. doi: 10.1210/jc.2016-1320.

46. Saeed A., Bartuzi P., Heegsma J., Dekker D., Kloosterhuis N., de Bruin A., Jonker J. W., van de Sluis B., Faber K. N. Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes. Cell. Mol. Gastroenterol. Hepatol. 2021, 11, 309-325. doi: 10.3390/nu12010228.

47. Lee S. A., Yuen J. J., Jiang H., Kahn B. B., Blaner W. S. Adipocyte-specific overexpression of retinol-binding protein 4 causes hepatic steatosis in mice. Hepatology. 2016, 64, 1534-1546. doi: 10.3390/ biology11081237.

48. Maevskaya M. V., Ivashkin V. T., Ivashkin K. V. et al. Nonalcoholic fatty liver disease as a cause and consequence of cardiometabolic complications. Features of pharmacotherapy. Place of ursodeoxycholic acid. Therapeutic Archives. 2019;91(2):109-117. (In Russ.) doi: 10.26442/004036 60.2019.02.000122. @@ Маевская М. В., Ивашкин В. Т., Ивашкин К. В. и др. Неалкогольная жировая болезнь печени как причина и следствие кардиометаболических осложнений. Особенности фармакотерапии. Место урсодезоксихолевой кислоты. Терапевтический архив. 2019;91(2):109-117. doi: 10.26442/004036 60.2019.02.000122.


Review

For citations:


Livzan M.A., Krolevets T.S., Syrovenko M.I. Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD). Experimental and Clinical Gastroenterology. 2023;(10):168-174. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-218-10-168-174

Views: 207


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)